Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

SIMPLE SUMMARY: The CD38-targeting antibody daratumumab has marked activity in multiple myeloma through direct anti-tumor effects and immunomodulatory activity. However, eventually most patients will develop daratumumab-refractory disease. We hypothesized that daratumumab-resistance could be reverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Frerichs, Kristine A., Verkleij, Christie P. M., Dimopoulos, Meletios A., Marin Soto, Jhon A., Zweegman, Sonja, Young, Mary H., Newhall, Kathryn J., Mutis, Tuna, van de Donk, Niels W. C. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158123/
https://www.ncbi.nlm.nih.gov/pubmed/34070044
http://dx.doi.org/10.3390/cancers13102452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158123/
https://www.ncbi.nlm.nih.gov/pubmed/34070044
http://dx.doi.org/10.3390/cancers13102452

Ejemplares similares